China Pharma Holdings, Inc. (CPHI)
USD 1.7
(13.04%)
USD 1.7
(13.04%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -504.88 Thousand USD | -2.22% |
| 2022 | -493.91 Thousand USD | -241.41% |
| 2021 | 349.27 Thousand USD | -82.12% |
| 2020 | 1.95 Million USD | 31.76% |
| 2019 | 1.48 Million USD | -24.95% |
| 2018 | 1.97 Million USD | -20.0% |
| 2017 | 2.46 Million USD | -23.3% |
| 2016 | 3.21 Million USD | 119.76% |
| 2015 | 1.46 Million USD | -45.11% |
| 2014 | 2.66 Million USD | -17.11% |
| 2013 | 3.21 Million USD | -77.13% |
| 2012 | 14.07 Million USD | -51.44% |
| 2011 | 28.98 Million USD | -4.28% |
| 2010 | 30.28 Million USD | 18.06% |
| 2009 | 25.65 Million USD | 1.42% |
| 2008 | 25.29 Million USD | 62.46% |
| 2007 | 15.56 Million USD | 54.17% |
| 2006 | 10.09 Million USD | 124.84% |
| 2005 | 4.49 Million USD | 18500.59% |
| 2004 | -24.4 Thousand USD | -122.17% |
| 2003 | 110.07 Thousand USD | 193.62% |
| 2002 | 37.49 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -290.02 Thousand USD | -105.09% |
| 2024 Q2 | -1.12 Million USD | -286.28% |
| 2023 Q2 | -146.66 Thousand USD | -182.43% |
| 2023 FY | -504.88 Thousand USD | -2.22% |
| 2023 Q1 | 177.92 Thousand USD | 316.86% |
| 2023 Q3 | -233.19 Thousand USD | -59.0% |
| 2023 Q4 | -141.41 Thousand USD | 39.36% |
| 2022 Q2 | -229.38 Thousand USD | -35.36% |
| 2022 Q3 | -137.75 Thousand USD | 39.94% |
| 2022 FY | -493.91 Thousand USD | -241.41% |
| 2022 Q1 | -169.46 Thousand USD | -156.12% |
| 2022 Q4 | 42.68 Thousand USD | 130.98% |
| 2021 FY | 349.27 Thousand USD | -82.12% |
| 2021 Q1 | 272.73 Thousand USD | -51.43% |
| 2021 Q2 | 71 Thousand USD | -73.97% |
| 2021 Q3 | -296.39 Thousand USD | -517.46% |
| 2021 Q4 | 301.93 Thousand USD | 201.87% |
| 2020 Q1 | 194.43 Thousand USD | -32.8% |
| 2020 FY | 1.95 Million USD | 31.76% |
| 2020 Q3 | 47.19 Thousand USD | -95.9% |
| 2020 Q2 | 1.14 Million USD | 491.34% |
| 2020 Q4 | 561.47 Thousand USD | 1089.66% |
| 2019 Q1 | 656.53 Thousand USD | 484.21% |
| 2019 FY | 1.48 Million USD | -24.95% |
| 2019 Q3 | 372.75 Thousand USD | 127.92% |
| 2019 Q2 | 163.54 Thousand USD | -75.09% |
| 2019 Q4 | 289.34 Thousand USD | -22.38% |
| 2018 FY | 1.97 Million USD | -20.0% |
| 2018 Q4 | -170.87 Thousand USD | -133.34% |
| 2018 Q3 | 512.54 Thousand USD | -11.55% |
| 2018 Q2 | 579.48 Thousand USD | -45.01% |
| 2018 Q1 | 1.05 Million USD | 54.77% |
| 2017 Q2 | 648.35 Thousand USD | -9.68% |
| 2017 Q3 | 421.53 Thousand USD | -34.98% |
| 2017 Q4 | 680.8 Thousand USD | 61.5% |
| 2017 FY | 2.46 Million USD | -23.3% |
| 2017 Q1 | 717.85 Thousand USD | -58.88% |
| 2016 Q4 | 1.74 Million USD | 398.8% |
| 2016 FY | 3.21 Million USD | 119.76% |
| 2016 Q1 | 640.81 Thousand USD | 360.16% |
| 2016 Q2 | 482.09 Thousand USD | -24.77% |
| 2016 Q3 | 349.96 Thousand USD | -27.41% |
| 2015 Q4 | 139.26 Thousand USD | -56.75% |
| 2015 Q2 | -55.82 Thousand USD | -105.27% |
| 2015 Q1 | 1.05 Million USD | 127.03% |
| 2015 FY | 1.46 Million USD | -45.11% |
| 2015 Q3 | 322 Thousand USD | 676.78% |
| 2014 Q1 | 2.66 Million USD | 564.14% |
| 2014 Q2 | 2.41 Million USD | -9.13% |
| 2014 Q3 | 1.5 Million USD | -37.57% |
| 2014 Q4 | -3.91 Million USD | -359.68% |
| 2014 FY | 2.66 Million USD | -17.11% |
| 2013 Q1 | -1.56 Million USD | -212.89% |
| 2013 Q2 | 2.15 Million USD | 237.05% |
| 2013 Q3 | 2.23 Million USD | 4.05% |
| 2013 Q4 | 400.57 Thousand USD | -82.1% |
| 2013 FY | 3.21 Million USD | -77.13% |
| 2012 Q4 | 1.38 Million USD | -57.16% |
| 2012 FY | 14.07 Million USD | -51.44% |
| 2012 Q3 | 3.24 Million USD | -21.62% |
| 2012 Q2 | 4.13 Million USD | -21.98% |
| 2012 Q1 | 5.3 Million USD | -27.55% |
| 2011 FY | 28.98 Million USD | -4.28% |
| 2011 Q4 | 7.32 Million USD | -2.57% |
| 2011 Q3 | 7.51 Million USD | 3.2% |
| 2011 Q2 | 7.28 Million USD | 6.0% |
| 2011 Q1 | 6.86 Million USD | -27.53% |
| 2010 Q4 | 9.47 Million USD | 24.32% |
| 2010 Q3 | 7.62 Million USD | 8.25% |
| 2010 FY | 30.28 Million USD | 18.06% |
| 2010 Q2 | 7.04 Million USD | 14.83% |
| 2010 Q1 | 6.13 Million USD | -15.49% |
| 2009 Q2 | 5.91 Million USD | -0.16% |
| 2009 FY | 25.65 Million USD | 1.42% |
| 2009 Q4 | 7.25 Million USD | 10.92% |
| 2009 Q3 | 6.54 Million USD | 10.55% |
| 2009 Q1 | 5.92 Million USD | -20.03% |
| 2008 Q2 | 5.95 Million USD | 2.51% |
| 2008 Q4 | 7.41 Million USD | 21.21% |
| 2008 FY | 25.29 Million USD | 62.46% |
| 2008 Q3 | 6.11 Million USD | 2.75% |
| 2008 Q1 | 5.8 Million USD | 29.39% |
| 2007 FY | 15.56 Million USD | 54.17% |
| 2007 Q4 | 4.48 Million USD | 15.66% |
| 2007 Q1 | 3.29 Million USD | -6.49% |
| 2007 Q2 | 3.89 Million USD | 18.21% |
| 2007 Q3 | 3.88 Million USD | -0.49% |
| 2006 Q2 | 1.87 Million USD | -15.25% |
| 2006 Q1 | 2.2 Million USD | 0.0% |
| 2006 Q3 | 2.49 Million USD | 33.34% |
| 2006 Q4 | 3.52 Million USD | 41.45% |
| 2006 FY | 10.09 Million USD | 124.84% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | 4.49 Million USD | 18500.59% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q3 | 976.66 Thousand USD | 0.0% |
| 2004 Q3 | - USD | 100.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | -24.4 Thousand USD | -122.17% |
| 2004 Q2 | -8046.00 USD | -233.48% |
| 2004 Q1 | 6028.00 USD | 141.12% |
| 2003 Q4 | 2500.00 USD | 110.05% |
| 2003 Q2 | 14.72 Thousand USD | 144.29% |
| 2003 Q1 | -33.25 Thousand USD | 6.91% |
| 2003 Q3 | -24.88 Thousand USD | -269.02% |
| 2003 FY | 110.07 Thousand USD | 193.62% |
| 2002 FY | 37.49 Thousand USD | 0.0% |
| 2002 Q4 | -35.71 Thousand USD | -149.88% |
| 2002 Q3 | 71.6 Thousand USD | 5126.5% |
| 2002 Q2 | 1370.00 USD | -84.11% |
| 2002 Q1 | 8624.00 USD | -64.96% |
| 2001 Q4 | 24.61 Thousand USD | 754.06% |
| 2001 Q3 | 2882.00 USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| cbdMD, Inc. | 14.97 Million USD | 103.371% |
| cbdMD, Inc. | 14.97 Million USD | 103.371% |
| Zomedica Corp. | 17.31 Million USD | 102.915% |